Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Efficacy based on dose-response and safety of bone marrow-derived mesenchymal stem cells for the treatment of osteoarthritis: a systematic review and meta-analysis

Lohrasbi E., Babaie S., Hamedfar H., Pourzeinali S., Toopchizadeh V., Farshbaf-Khalili A.

Meta-analysis with a reported sample of 1150 on Osteoarthritis, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Stem Cell Res Ther (2025)
Reported sample size
1150
Source database
Europe PMC
PMID
41361483
PMCID
PMC12683818
DOI
10.1186/s13287-025-04799-0

Abstract (original English)

Introduction In recent years, the use of mesenchymal stem cells (MSCs), especially those derived from bone marrow and embryonic sources, has been considered as an emerging therapeutic approach for repairing joint tissue and reducing osteoarthritis symptoms. This systematic review and meta-analysis evaluated bone marrow-derived mesenchymal stem cells (BM-MSCs) efficacy, safety, and optimal dosing for osteoarthritis treatment. Methods Thirteen randomized trials of the 1427 articles identified (11 meta-analyzed; n = 1150 patients) were identified via PubMed, Scopus, Embase, and other databases (search updated to May 2025). The primary outcomes were the optimal dose of BM-MSCs in improving pain intensity (VAS), WOMAC scores (pain, stiffness, function, total score), and their safety, analyzed using RevMan 5.4. Cochrane risk-of-bias assessment guided quality appraisal. Results BM-MSCs showed no significant pain reduction (VAS) or functional improvement (WOMAC) at 1-3 months' post-injection. Significant improvements emerged at 6 months, peaking at 12 months: VAS decreased by WMD - 2.31 (95% CI - 3.83 to - 0.80; P = 0.003), and WOMAC total score reduced by WMD - 10.14 (95% CI - 18.26 to - 2.02; P = 0.01). Subgroup analyses indicated optimal doses of ≤ 25 × 10⁶ cells for VAS improvement and ≤ 25 × 10⁶ or 25-50 × 10⁶ cells for WOMAC total score at 12 months. Safety profiles were favorabl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Bone Marrow CellsMesenchymal Stem CellsHumansOsteoarthritisTreatment OutcomeMesenchymal Stem Cell TransplantationRandomized Controlled Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research